Extravascular ICD Pilot Study (EV ICD)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
The study will recruit male and female adult subjects that meet all of the inclusion criteria and none of the exclusion criteria. All subjects will be indicated to receive an ICD.
The EV ICD system will be implanted and the subjects will be followed for at least 3 months following implantation of the system.
Subjects will be exited after follow-up is completed.
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Brisbane, Australia
- The Prince Charles Hospital
-
Clayton, Australia
- MonashHeart
-
Heidelberg, Australia
- Austin Health
-
-
-
-
-
Christchurch, New Zealand
- Christchurch Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patient has a Class I or IIa indication for implantation of an ICD according to the ACC/AHA/HRS Guidelines[1]
- Patient is willing and able to sign and date the Informed Consent Form.
- Patient is at least 18 years of age and meets age requirements per local law
- Patient is geographically stable and willing and able to comply with the study procedures and visits for the duration of the follow-up
[1] Al-Khatib SM, Stevenson WG, Ackerman MJ, Bryant WJ, Callans DJ, Curtis AB, Deal BJ, Dickfeld T, Field ME, Fonarow GC, Gillis AM, Hlatky MA, Granger CB, Hammill SC, Joglar JA, Kay GN, Matlock DD, Myerburg RJ, Page RL. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias
-
Exclusion Criteria:
- Patient has indications for bradycardia pacing [1] or Cardiac Resynchronization Therapy (CRT) [2] (Class I, IIa, or IIb indication)
- Patient has an existing or had a prior pacemaker, ICD, or CRT device implant or leads
Patient has anatomical abnormality that significantly increases implant risk[3] including:
• Severe obesity [4]
- Marked RV dilation
- Marked sternal abnormality
- Hiatus hernia that distorts mediastinal anatomy
- Patient has prior chest radiotherapy
- Patient had previous mediastinitis
- Patient had previous coronary artery bypass grafting procedure
- Patient has existing transcatheter aortic valve replacement
- Patient has gastrostomy tube
- Patient has had a prior sternotomy, prior mediastinal instrumentation, prior abdominal surgery in the epigastric region, or planned sternotomy
Patient has previous pericarditis that:
• Was chronic and recurrent, or
• Resulted in pericardial effusion [5], or
• Resulted in pericardial thickening or calcification [6]
Patients with a medical condition that precludes them from undergoing defibrillation testing, such as:
• known LV thrombus
• decompensated heart failure
- LVEF <20% [7]
- other physician discretion
- Patient has persistent Atrial Fibrillation who is at high risk of a thromboembolic event with a CHA₂DS₂-VASc score ≥3, or is contraindicated for having anticoagulation interrupted for ≥72 hours
Patients with comorbidities which may increase surgical risk of complications[8] including:
• severe aortic stenosis
- COPD and is oxygen dependent
- Hepatosplenomegaly
- Marked hepatomegaly
- Patient is on renal dialysis
- Patient with any evidence of active infection or undergoing treatment for an infection
- Patient with current implantation of neurostimulator or any other chronically implanted device which uses current in the body.
- Patients with a limited life expectancy of less than 12 months
- Patient is enrolled or planning to enroll in a concurrent drug or device study that may confound the results of this study, without documented pre-approval from a Medtronic study manager
- Patient with any exclusion criteria as required by local law (e.g., age, pregnancy, breast feeding)
- Pregnant women or breastfeeding women, or women of child bearing potential and who are not on a reliable form of birth regulation method or abstinence [9]
[1] 2015 HRS/EHRA/APHRS/SOLAECE expert consensus statement on optimal implantable cardioverter-defibrillator programming and testing).
[2] ACC/AHA/HRS guidelines for Cardiac Resynchronization Therapy [3] Per physician discretion [4] BMI > 40 [5] As documented on echo or MRI [6] As documented on CT scan or MRI [7] Most recent LVEF in the last 180 days (inclusive) [8] Per physician discretion [9] if required by local law, women of child-bearing potential must undergo a pregnancy test within seven days prior to EV ICD Pilot Study procedures
-
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Experimental
Patients will be implanted with an extravascular ICD and undergo requisite electrical testing.
|
VT/VF induction attempted for defibrillation testing, as well as requisite electrical testing.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Efficacy Outcome - Number of Participants That Had Successful Termination of Ventricular Fibrillation Episodes at Implantation
Time Frame: At Implantation
|
Each subject will demonstrate a successful defibrillation outcome if either 2 successive induced ventricular fibrillation episodes are terminated by the subject's device delivering a shock at the required energy level, or if one such episode is successfully terminated by the subject's device delivering a shock at a lower energy level.
Up to 5 such episodes may be induced to test device efficacy.
|
At Implantation
|
|
Safety Outcome - Percentage of Participants With Freedom From Major System and Procedure Related Complications at 3 Months (90 Days)
Time Frame: 3 months (90 days)
|
Subjects will be monitored to determine whether they experience a major procedure- or system-related complication within 3 months (90 days) post-implant.
|
3 months (90 days)
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Ian G Crozier, MB ChB, Christchurch Hospital, Christchurch, New Zealand
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- MDT17034
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Tachycardia
-
NCT05820035CompletedParoxysmal Supraventricular Tachycardia | Atrioventricular Nodal Reentrant Tachycardia | Atrioventricular Reciprocating Tachycardia
-
NCT04078685UnknownTachycardia, Supraventricular | Tachycardia; Paroxysmal, Supraventricular
-
NCT07617077RecruitingSupraventricular Tachycardia | Paroxysmal Supraventricular Tachycardia | Atrioventricular Nodal Reentry Tachycardia | Vagal Maneuver
-
NCT04392362Completed
-
NCT01426425CompletedHeart Disease | Supraventricular Tachycardia | AtrioVentricular Nodal Reentrant Tachycardia
-
NCT06717685RecruitingSupraventricular Tachycardia (SVtach)
-
NCT01584154UnknownSupraventricular Tachycardia | Atrioventricular Nodal Reentrant Tachycardia
-
NCT02296190CompletedParoxysmal Supraventricular Tachycardia (PSVT)
-
NCT03353610TerminatedParoxysmal Supraventricular Tachycardia (PSVT)
-
NCT07456423CompletedSupraventricular Tachycardia (SVT) | Atrioventricular Nodal Re Entrant Tachycardia
Clinical Trials on Defibrillation using the Extravascular ICD
-
NCT05049720WithdrawnTachycardia | Ventricular Arrythmia
-
NCT07091916CompletedTachycardia | Ventricular Arrythmia
-
NCT06048731Active, not recruitingTachycardia | Ventricular Arrhythmia
-
NCT02513030UnknownDefibrillation Capacity of Defibrilators After Replacement
-
NCT04011631CompletedVentricular Fibrillation | Ventricular Tachycardia
-
NCT00180271CompletedTachycardia | Congestive Heart Failure
-
NCT04132466CompletedDeath, Sudden, Cardiac
-
NCT02111993CompletedEvaluating Myocardial Injury for Defibrillation Threshold Testing Methods for ICD Implantation (ULV)Heart Failure | Cardiac Arrhythmia | Cardiomyopathy